Long COVIDEAV-LONGCOVIDNCT07343856
Long COVID Diagnostic Reactivity Assesment Test
A study testing Electrodiagnostic Bioelectrical Assessment in people with Long COVID and Post-Acute Sequelae of SARS-CoV-2 Infection, run by Oncology Center,Ministry Of Heath,Uzbekistan at 1 site in Uzbekistan.
Trial summary
This study is a diagnostic clinical investigation designed to evaluate bioelectrical response patterns assessed by electro-acupuncture-based medicament testing. The method is used to identify individual bioelectrical reactivity associated with the presence and persistence of pathological factors and to assess… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Long COVID, Post-Acute Sequelae of SARS-CoV-2 Infection
- What is being tested?
- Electrodiagnostic Bioelectrical Assessment
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteUzbekistan
- Study dates
- 5 Dec 2025to 1 Jan 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years or older
- History of confirmed SARS-CoV-2 infection
- Persistent symptoms consistent with Long COVID lasting ≥12 weeks after acute infection
- Ability to provide informed consent
- Willingness to undergo non-invasive bioelectrical diagnostic assessment
Who cannot join
- Acute infectious disease at the time of enrollment
- Severe uncontrolled medical or psychiatric conditions that may interfere with diagnostic assessment
- Implanted electronic medical devices (e.g., pacemaker)
- Pregnancy or breastfeeding
- Inability to comply with study procedures
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Development of a Personalized Alternative Non-invasive Rapid Diagnostic Test for SARS-CoV-2 in Patients With Long COVID
This study is a diagnostic clinical investigation designed to evaluate bioelectrical response patterns assessed by electro-acupuncture-based medicament testing.
The method is used to identify individual bioelectrical reactivity associated with the presence and persistence of pathological factors and to assess patient-specific responses to tested medicinal substances.
The study involves a single-session, non-invasive diagnostic procedure without administration of pharmacological treatment. The primary objective is the methodological evaluation of the diagnostic approach and the characterization of the detected bioelectrical response patterns in the studied population.
Read the detailed description
This study is a diagnostic clinical investigation designed to evaluate bioelectrical response patterns assessed by electro-acupuncture-based medicament testing.
The method is used to identify individual bioelectrical reactivity associated with the presence and persistence of pathological factors and to assess patient-specific responses to tested medicinal substances.
The study involves a single-session, non-invasive diagnostic procedure without pharmacological treatment. The primary objective is the methodological evaluation of the diagnostic approach and the characterization of the detected bioelectrical response patterns in the studied population.
- Being tested
- Electrodiagnostic Bioelectrical Assessment
- Keywords
- Long COVID, Post-acute sequelae of SARS-CoV-2 infection, Bioelectrical assessment, Electroacupuncture diagnostics, Medicament testing, Autonomic dysregulation, Chronic viral persistence, Non-invasive diagnostics
- Medical subject headings
- Post-Acute COVID-19 Syndrome, Primary Dysautonomias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Electrodiagnostic Bioelectrical AssessmentDiagnostic test
A non-invasive diagnostic procedure performed during a single session to assess bioelectrical response patterns associated with viral antigen persistence. Measurements are obtained using standardized bioelectrical assessment techniques without administration of any therapeutic agents or interventions.
| Study group | Role | What they receive |
|---|---|---|
| Diagnostic Assesment Arm | Experimental | This single-arm study includes participants undergoing a non-invasive electrodiagnostic assessment to evaluate bioelectrical response patterns associated with viral antigen persistence. No therapeutic intervention is administered. Receives: Diagnostic Test: Electrodiagnostic Bioelectrical Assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Bioelectrical Response Patterns Consistent With Viral Persistence
Non-invasive diagnostic assessment using electroacupuncture-based medicament testing to identify bioelectrical response patterns consistent with viral antigen persistence in participants with post-viral conditions.
Measured: At enrollment (single diagnostic session)
Secondary outcomes (1)
Distribution of Bioelectrical Reactivity Patterns During Medicament Testing
Measured: Baseline(Day 1)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2026
- Study start5 Dec 2025
- Primary completion30 Dec 2026 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Long COVIDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- All enrolled participants undergo a single-session diagnostic assessment using medicament testing to evaluate bioelectrical response patterns associated with viral persistence.
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Oncology Center,Ministry Of Heath,Uzbekistan
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Naylya Djumaeva, MD,PhD, Principal investigator, Reseacrh Institute of Virology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07343856
- Sponsor's protocol ID
- 9/36-2216
- Acronym
- EAV-LONGCOVID
- Status last verified
- Dec 2025
- First submitted
- 24 Dec 2025
- Last updated
- 15 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No